Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guido Marcucci

Showing results (311-320 of 536) with videos related to

Pageof 54
Sort By:
Blood|June 2, 2019
ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse modelChi-Ling Chiang, Swagata Goswami, Frank W Frissora, et al.
The Journal of Clinical Investigation|September 19, 2006
Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterationsAdrienne M Dorrance, Shujun Liu, Weifeng Yuan, et al.
Oncotarget|August 13, 2016
Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemiaXiaomeng Huang, Sebastian Schwind, Ramasamy Santhanam, et al.
American Journal of Hematology|July 2, 2019
Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemiaIbrahim Aldoss, Dongyun Yang, Raju Pillai, et al.
Blood|August 27, 2013
Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemiaLiat Goldberg, Marloes R Tijssen, Yehudit Birger, et al.
Blood Advances|February 25, 2020
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801Guido Marcucci, Susan Geyer, Kristina Laumann, et al.
The AAPS Journal|November 27, 2012
In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemiaHongyan Wang, Ping Chen, Jiang Wang, et al.
Leukemia & Lymphoma|April 18, 2024
High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapyJose Tinajero, Dat Ngo, Jianying Zhang, et al.
Experimental Hematology & Oncology|April 11, 2025
Correction: AOH1996 targets mitochondrial dynamics and metabolism in leukemic stem cells via mitochondrial PCNA inhibitionHyunJun Kang, Melissa Valerio, Jia Feng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemiaRebecca B Klisovic, Wendy Stock, Spero Cataland, et al.
Pageof 54

Showing results (311-320 of 536) with videos related to

Sort By:
Pageof 54
Blood|June 2, 2019
ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse modelChi-Ling Chiang, Swagata Goswami, Frank W Frissora, et al.
The Journal of Clinical Investigation|September 19, 2006
Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterationsAdrienne M Dorrance, Shujun Liu, Weifeng Yuan, et al.
Oncotarget|August 13, 2016
Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemiaXiaomeng Huang, Sebastian Schwind, Ramasamy Santhanam, et al.
American Journal of Hematology|July 2, 2019
Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemiaIbrahim Aldoss, Dongyun Yang, Raju Pillai, et al.
Blood|August 27, 2013
Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemiaLiat Goldberg, Marloes R Tijssen, Yehudit Birger, et al.
Blood Advances|February 25, 2020
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801Guido Marcucci, Susan Geyer, Kristina Laumann, et al.
The AAPS Journal|November 27, 2012
In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemiaHongyan Wang, Ping Chen, Jiang Wang, et al.
Leukemia & Lymphoma|April 18, 2024
High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapyJose Tinajero, Dat Ngo, Jianying Zhang, et al.
Experimental Hematology & Oncology|April 11, 2025
Correction: AOH1996 targets mitochondrial dynamics and metabolism in leukemic stem cells via mitochondrial PCNA inhibitionHyunJun Kang, Melissa Valerio, Jia Feng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemiaRebecca B Klisovic, Wendy Stock, Spero Cataland, et al.
Pageof 54